Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 19;42(5):1755–1766. doi: 10.3892/or.2019.7282

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 6. — Synergistic effect of BCL-2 inhibitor and myddosome assembly inhibitor on ABC DLBCL cells. (A, B) OCI-LY10 cells were treated for 72 h with ABT-199, ST2825 or both, at the indicated doses, followed by a WST-1 assay. Inhibition at varying dosimetries for the inhibitor of BCL-2 (ABT-199) and MYD88 (ST2825) in OCI-LY10 cells is depicted with (A) heat maps and (B) line graphs. (C) Synergism was evaluated via CI analysis, and the CI values of OCI-LY10 cells at varying dosimetry values for ABT-199 and ST2825 are demonstrated via heat maps. (D) Apoptotic cell population (annexin V-positive) of OCI-LY10 cells analyzed by flow cytometry, following treatment for 48 h with the vehicle, ST2825 (10 µM), ABT-199 (1 µM) or combination treatment. Statistical analysis by one-way ANOVA with Tukey's post hoc test. Data are presented as the mean ± standard deviation *P<0.05. BCL-2, B-cell lymphoma-2; ABC, activated B cell; DLBCA, diffuse large B-cell lymphoma; MYD88, myeloid differentiation primary response gene 88; CI, combination index.